AstraZeneca (AZN) CFO Sells Shares at £115.117 — 6-K Notice

AstraZeneca PLC reported a notification that its Executive Director and Chief Financial Officer, Aradhana Sarin, executed a sale of the company’s ordinary shares on 14 August 2025.

Rhea-AI Filing Summary

AstraZeneca PLC reported a notification that its Executive Director and Chief Financial Officer, Aradhana Sarin, executed a sale of the company’s ordinary shares on 14 August 2025. The filing, provided on 18 August 2025, discloses a transaction price of £115.117 per share. The announcement follows EU Market Abuse Regulation reporting requirements as incorporated into UK law. The notice does not clearly state the number of shares sold in the visible text, so the total proceeds and percentage ownership change are not determinable from this filing alone.

Positive

• Regulatory compliance—transaction was disclosed under the EU Market Abuse Regulation
• Named officer identified: Aradhana Sarin, Executive Director and Chief Financial Officer

Negative

• Missing quantity—the filing does not state the number of shares sold, preventing assessment of materiality
• Insider sale by the CFO could be interpreted negatively by some investors absent context

Insights

Corporate Governance Analyst

Routine insider sale disclosed; filing meets regulatory transparency requirements.

Insider transactions by senior officers are commonly disclosed to satisfy market-abuse and disclosure rules. The filing names the seller, the role (Chief Financial Officer), the transaction date (14 August 2025), and a transaction price of £115.117.

The absence of a clear quantity in the visible text prevents calculation of proceeds or change in ownership, limiting investor assessment. Monitor subsequent disclosures or the detailed EU Market Abuse Regulation notification for the exact volume and resulting ownership percentages within days.

FAQ

What did AstraZeneca (AZN) disclose in the Form 6-K dated 18 August 2025?

The company disclosed that CFO Aradhana Sarin sold ordinary shares on 14 August 2025 at a reported price of £115.117 per share.

How many AstraZeneca (AZN) shares did the CFO sell?

The visible text of the filing does not specify the quantity sold, so the number of shares is not available in this document.

Does the filing explain the reason for the CFO's sale?

No reason for the sale is provided in the filing; it only reports the transaction details required by disclosure rules.

Is the transaction price for the sale disclosed for AZN insider trade?

Yes, the filing lists a transaction price of £115.117 per share.

Where can investors find the full insider notification for more details?

The filing states the notification was made in accordance with the EU Market Abuse Regulation; investors should consult the attached or subsequent detailed notification for exact volume and ownership impact.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/18/2025 - 11:07 AM Learn about SEC filing dates

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934

For the month of August 2025 

Commission File Number: 001-11960

AstraZeneca PLC

1 Francis Crick Avenue

Cambridge Biomedical Campus

Cambridge CB2 0AA

United Kingdom

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F X Form 40-F __

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes __ No X

If “Yes” is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-_____________

AstraZeneca PLC

INDEX TO EXHIBITS

1. Director/PDMR Shareholding

18 August 2025

Transaction by Person Discharging Managerial Responsibilities

AstraZeneca PLC (the Company) announces that, on 15 August 2025, it was notified of a transaction in the Company's ordinary shares of $0.25 each (Ordinary Shares), by Aradhana Sarin, Executive Director and Chief Financial Officer, on 14 August 2025, as set out below.

PDMR	Position	Nature of the transaction	Quantity	Price per Ordinary Share
Aradhana Sarin	Executive Director and Chief Financial Officer	Sale of Ordinary Shares	9563	£115.117

Further details are set out in the attached notification, made in accordance with the requirements of the EU Market Abuse Regulation (as it forms part of UK law pursuant to the European Union (Withdrawal) Act 2018.

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Aradhana Sarin
2	Reason for the notification
a)	Position/status	Chief Financial Officer
b)	Initial notification/Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	AstraZeneca PLC
b)	LEI	PY6ZZQWO2IZFZC3IOL08
4i	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Ordinary Shares of US$0.25 each in AstraZeneca PLC GB0009895292
b)	Nature of the transaction	Sale of Ordinary Shares of US$0.25 each in AstraZeneca PLC
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£115.117	9563
d)	Aggregated information - Aggregated volume - Price	Not applicable - single transaction
e)	Date of the transaction	14 August 2025
f)	Place of the transaction	LON

AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on social media @AstraZeneca

Contacts

For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.

Matthew Bowden

Company Secretary

AstraZeneca PLC

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AstraZeneca PLC

Date: 18 August 2025

By: /s/ Matthew Bowden

Name: Matthew Bowden

Title: Company Secretary